Four Beijing volunteers test SARS vaccine
China started its first human trials for a new SARS vaccine on Saturday with four volunteers, the first batch of the 30 selected, being vaccinated in a hospital in Beijing.
"The four volunteers calmly received vaccination against severe acute respiratory syndrome (SARS) in the heavily guarded second-floor of the China-Japan Friendship Hospital," Xinhua reported.
The vaccine used for the volunteers was produced by Beijing-based Sinovac Biotech Co Ltd, a company authorized by the State Food and Drug Administration (SFDA).
The vaccine was found to be safe and effective in experiments on animals, including the rhesus monkey, which has a more similar immune system to humans than other animals.
The first phase of the test is to determine if it is safe and effective for humans. There were still risks, experts said.
A special committee has been set up to protect the rights of the volunteers, who may participate or withdraw from the test at will.
Researchers will provide medical treatment if the volunteers suffer any adverse effects.
The second phase of clinical testing will involve more participants.
In February, the SFDA authorized Sinovac to select volunteers for China's first clinical testing of the vaccine. It only sets the standard number of volunteers needed for the first clinical testing, but does not select the actual volunteers.
The first phase of the testing will last three months in Beijing, South China's Guangdong Province or the Guangxi Zhuang Autonomous Region.